NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised

What happened: Novo NVO reported adjusted Q3 2026 earnings of 89 cents per ADR, beating the Zacks Consensus Estimate of 81 cents, and raised its 2026 outlook on higher GLP-1 sales expectations. Key numbers: Adjusted EPS 89 cents vs 81 cents estimate, down 12% year over year. Why it matters: The raised outlook reflects improving momentum in the obesity franchise, with the Wegovy pill providing an additional growth avenue as injectable sales face pricing pressure. Weakness in the diabetes franchise, particularly Ozempic, and intensifying GLP-1 competition remain headwinds. Market: +1.0% today ($8.37), +314.4% YTD, 0.1x vol — as of 15:18 UTC

Novo NVO reported adjusted Q3 2026 earnings of 89 cents per ADR, beating the Zacks Consensus Estimate of 81 cents, and raised its 2026 outlook on higher GLP-1 sales expectations.

The raised outlook reflects improving momentum in the obesity franchise, with the Wegovy pill providing an additional growth avenue as injectable sales face pricing pressure. Weakness in the diabetes franchise, particularly Ozempic, and intensifying GLP-1 competition remain headwinds. Market: +1.0% today ($8.37), +314.4% YTD, 0.1x vol — as of 15:18 UTC